Acer Therapeutics secures $8.5 mln in Series B led by TVM Life Science
TVM Life Science Venture VII led an $8.15 million Series B financing in Acer Therapeutics Inc., a pharmaceutical company developing therapies for rare disorders. The proceeds will be used to prepare a new drug application for a vascular syndrome and to develop a treatment for two series genetic diseases. Luc Marengere, managing partner of TVM Life Science Capital, joins the board, alongside Cynthia Lavoie, who led investments by TVM Life Science Venture VI into the Series A and B rounds.
10 May 2016•4 mins read
